42 results about "Molecular biomarkers" patented technology

A method and system for medical imaging of neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD), autism, and schizophrenia. Noninvasive, in vivo methods identify novel brain molecular biomarkers of normal neurodevelopment in order to determine molecular underpinnings of abnormal neurodevelopment. The described brain molecular biomarkers will aid in the presymptomatic diagnosis of neuropsychiatric disorders which begin in childhood and adolescence, such as ADHD, autism, and schizophrenia.

In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.

The invention discloses an aqueous phase preparation method for a chitosan-quantum dot fluorescent probe, which comprises the following steps of: A, preparing solution of carboxymethyl chitosan: weighing carboxymethyl chitosan, dissolving in a beaker by using double distilled water, and fixing the volume in a bottle for later use; B, preparing solution of CdTe quantum dot: according to the concentration of CdTe quantum dot, transferring the CdTe quantum dot solution to the beaker by using a transfer pipette, adding double distilled water, regulating the pH value to be 7-13, and fixing the volume in a bottle for later use; and C, mixing the prepared carboxymethyl chitosan solution and the CdTe quantum dot solution according to different volume ratios, shaking uniformly and standing at room temperature, or performing ultrasonic wave reaction, oscillating reaction or microwave heating reaction to obtain chitosan-quantum dot fluorescent probes with corresponding luminous wavelengths and different fluorescence intensities. The preparation method has the advantages of simple operation, good water solubility of products, long stabilization time, high yield of fluorescence quantum, good cellular compatibility, and wide application in the aspects of cell and macro-molecular biomarkers.

Methods and compositions for diagnosing chronic kidney disease and assessing the risk of disease progression, as well as methods of screening for molecular biomarkers useful for diagnosing the likelihood of disease progression, are provided.

The present invention provides devices and methods for detecting and capturing molecular biomarkers from a subject in situ. Specifically, the devices contain an array of microneedles to which are attached probes specific for one or more biomarkers of interest. The devices can be used directly on a subject (e.g., via skin piercing) in detecting the biomarkers in the body of the subject (e.g., tissues, blood stream).

A noninvasive method for diagnosing skin health in a subject comprising collecting a skin sample from the subject; detecting a level of one or more small molecule biomarkers in the epithelial cell sample/skin cell sample; diagnosing the subject as having a skin condition based on the level of a detected small molecule biomarker, wherein the detected small molecule is at least one compound chosen from: a compound generated by metabolism of amino acids, a compound generated by dipeptides metabolism, a compound generated by nucleic acids, a compound generated by metabolism of lipids, a compound generated by metabolism of carbohydrates, and mixtures thereof and further small molecule biomarkers as listed in Table 1. Further, a noninvasive method for evaluating the efficacy of products for skin health.

The invention discloses a three-dimensional SERS (surface enhanced raman scattering) substrate based on a macromolecular brush/metal nanometer particle composite film and a preparation method thereof. The preparation method of the substrate comprises the following steps of soaking POEGMA brushes into a metal nanometer particle solution for 20min to 12h; performing rinsing for multiple times by ultrapure water; performing drying through blowing by N2; then, soaking the POEGMA brushes into a metal nanometer particle solution; repeatedly performing the soaking-rinsing-blow drying-soaking process for 1 to 36 times; through a layer-by-layer stacking principle, compounding the nanometer particles into the macromolecular brushes by using the replacement effect of the EG groups of the POEGMA and citrates on the surface of the metal nanometer particles. The substrate is particularly applicable to the detection of micromolecular biological markers and bacterial detection. The preparation method provided by the invention is simple; the implementation is easy; the operability is high. The prepared SERS substrate has low cost, high Raman enhancement characteristics, excellent sensitivity and excellent stability.

By a genome-wide gene analysis of expression profiles of known or putative gene sequences in kidney biopsy samples, the present inventors have identified a consensus set of gene expression-based molecular biomarkers for distinguishing kidney transplantation patients who have Acute Rejection (AR), Acute Dysfunction No Rejection (ADNR), Chronic Allograft Nephropathy(CAN), or Transplant Excellent/Normal (TX). These molecular biomarkers are useful for diagnosis, prognosis and monitoring of transplantation patients.

The invention provides a prediction method of the physical properties of underground biodegradable thickened oil. The method comprises the steps that 1, selecting crude oil samples, extracting molecular biomarkers to carry out quantitative test analyses and comparison, and then judging biodegradation degree of crude oil; 2, screening sensitive molecule biomarker maturity parameters with high biodegradation resistance; 3, building a quantitative relationship model between the biomarker parameters and crude oil physical properties. For the crude oil from the same source rock, thermal maturity is a main determiner influencing the chemical composition and physical properties of the crude oil. According to an oil deposit geochemical principle, the molecule biomarker maturity parameters can well reflect minute maturity changes among oil deposits, while the physical properties of the underground crude oil is controlled by the thermal maturity to a great degree. Therefore the biomarker maturity parameters not influenced by biodegradation are screened to build the relationship model with the physical properties of biodegradable crude oil, thus predicting the physical properties of the underground biodegradable thickened oil.

The invention discloses a method for cloning cytochrome oxidase gene of Nereis bidentata, which is to clone the total RNA of Nereis bidentata body wall muscle by designing specific fragment amplification and RACE amplification. The cytochrome oxidase gene of Nereis dentata can be detected by real-time fluorescent quantitative PCR technology under the stress of persistent organic pollutants. The mechanism of oxidase gene expression and regulation provides a basis, and also lays the foundation for screening molecular biomarkers for early ecological risk prediction of marine sediment environmental pollution, which is conducive to the wide application of the low-cost and abundant sources of the clamworm in environmental protection.

The invention relates to a method for screening biomarkers of ionizing radiation as well as an application of SZT2 protein determined by the method to preparation of a molecular biomarker kit for personnel exposed to heavy ion radiation. The method comprises the following steps: screening differentially expressed genes in human cells which are treated with heavy ion irradiation by using a genechip method; screening differentially expressed proteins in cells of the same type which are treated with heavy ion irradiation by using iTRAQ technology; comparing screening results, and from the genes and the proteins which are differentially expressed simultaneously, selecting differentially expressed protein SZT2 which is down-regulated both in gene and protein levels as the biomarker of ionizing radiation. The genechip method and iTRAQ technology are combined, categories and quantities of genes and proteins in cell specimens of experimental groups of different dosages and a control group are compared and analyzed, the differentially expressed protein SZT2 which is down-regulated both in gene and protein levels can be rapidly found, and the protein can be used as a significant biomarker of ionizing radiation.

The invention discloses a cloning method of a perinereis aibuhitensis metal binding protein gene. According to the invention, a specific segment amplification method and a RACE amplification method are designed, and a perinereis aibuhitensis metal binding protein gene is cloned from perinereis aibuhitensis body wall muscle total RNA. With the method, the MP II gene expression regularity of perinereis aibuhitensis suffered from stresses of pollutants such as heavy metals can be detected with a real-time fluorescence quantitative PCR technology. Therefore, the method provides a basis for the study of the mechanism of heavy metal regulation on perinereis aibuhitensis MP II gene. Also, the method assists in establishing a basis for screening molecular biomarkers for marine sedimentary environment pollution early-stage ecological risk forecasting. With the method, perinereis aibuhitensis with a low cost and an abundant source can be widely applied in environment protection.

Methods for predicting the outcome of and monitoring prostate cancer patients using prostate specific antigen (PSA) proteolytic activity (PPA) in combination with other molecular biomarkers or other parameters are described. Methods of determining sets of parameters for use in predicting the outcome of and monitoring of prostate cancer patients are also described.

The invention discloses a renal cell carcinoma biomarker. As a metastasis marker, the renal cell carcinoma biomarker is used for diagnosing and/or evaluating renal cell carcinoma prognosis and the risk of metastasis; or, as a specific molecular target of the renal cell carcinoma, the renal cell carcinoma biomarker is applied to treatment of the renal cell carcinoma; and the biomarker comprises oneor more of THBS2, SCGB1A1, NKX2-1, COL11A1, DCN, COL1A1 and SFTPB. By detecting the expression levels of THBS2, SCGB1A1, NKX2-1, COL11A1, DCN, COL1A1 and SFTPB in tissue of a renal cell carcinoma patient, whether the renal cell carcinoma patient has metastasis or not and prognosis can be judged, and the accuracy rate reaches 93% or more. Therefore, the disease progression, metastasis and prognosis of the renal cell carcinoma patient can be evaluated by detecting molecular biomarkers including the THBS2 and the like in the tissue of the renal cell carcinoma patient, and thus, symptomatic related treatment can be performed in time, the survival time and quality of the patient are respectively extended and improved; and the renal cell carcinoma biomarker has relatively great economic value and social benefits.

The invention provides an application of urine TIMP-2 in preparation of a biomarker for diagnosing sepsis acute kidney injury. The invention also provides application of IGFBP-7 in preparation of a biomarker for diagnosing sepsis acute kidney injury. The invention further provides application of the urine TIMP-2 combined with IGFBP-7 in preparation of a biomarker for diagnosing sepsis acute kidneyinjury. The invention further provides a kit for detecting acute kidney injury caused by sepsis diagnosis. The kit contains reagents for detecting TIMP-2 and IGFBP-7 in a body fluid sample. It is found that the content of urine IGFBP-7 and TIMP-2 in clinical sepsis AKI patients is remarkably higher than that of urine IGFBP-7 and TIMP-2 in health examination and non-AKI group patients; through ROCcurve analysis, it is found that urine IGFBP-7 and TIMP-2 have high benefits in diagnosis of acute kidney injury caused by sepsis as molecular biomarkers.

The invention discloses a renal cell carcinoma miRNA molecular marker which is used as a metastasis marker and is used for diagnosing and/or evaluating prognosis and metastasis risks of renal cell carcinoma, or as a specific molecular target of the renal cell carcinoma which is applied to treatment of the renal cell carcinoma; wherein the miRNA molecular marker comprises one or more of miR-328, miR-502 and miR-504. By detecting the expression level of miR-328, miR-502 and/or miR-504 in the tissue of a renal cell carcinoma patient, whether the renal cell carcinoma patient has metastasis or not and prognosis can be judged, and the accuracy rate reaches 95% or above. Therefore, by detecting miR-328, miR-502 and/or miR-504 and other molecular biomarkers in the tissue of the renal cell carcinoma patient, the disease progression, metastasis and prognosis of the renal cell carcinoma patient can be evaluated, related treatment can be carried out on symptoms in time, the survival time and quality of life of the patient are improved, and great economic value and social benefits are achieved.

The invention relates to a method for predicting the response to the treatment with an EGFR tyrosine kinase inhibitor of a patient suffering lung cancer an carrying a mutation in the EGFR gene based on the expression levels in a sample of said patient of the BRCA1 gene wherein low BRCA1 expression levels are indicative of a positive response of a patient. This positive response is also observed in patients showing the T790M mutation in the EGFR gene which is usually associated with resistance to EGFR tyrosine kinase inhibitors.

Ovarian, cervical cancer, endometriosis, clear cell renal carcinoma cancers are very heterogeneous diseases which lack robust diagnostic, prognostic and predictive clinical biomarkers. Conventional clinical biomarkers (stages, grades, tumor mass etc) and molecular biomarkers (CA125, KRAS, p53 etc) are not appropriate for early diagnostics, differential diagnostics, prediction and prognosis of the disease outcome for individual patients. The most common type of the human ovarian cancers is human epithelial ovarian cancer (EOC). This cancer is characterized with one of the lowest survival rates compared to other cancers. The present invention relates to an in vitro method for diagnosing epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and/or predisposition to epithelial ovarian cancer in a subject, the method comprising determining in a sample of the subject gene expression level of at least one gene in the MDS1 and EVI1 complex (MECOM) locus; and/or copy number of at least one gene in the MECOM locus; wherein the level against at least one expression cutoff value and/or copy number against at least one copy number cutoff value are indicative of the subject having epithelial ovarian cancer, cervical cancer, endometriosis, clear cell renal carcinoma and/or a predisposition to epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and/or determining whether the ovarian cancer in the subject is primary or secondary ovarian cancer and/or a risk of the disease progression after surgery treatment, and/or an effectiveness of post-surgery chemotherapy.

The invention discloses an ovarian cancer evaluation method based on biomarkers, which includes the following steps: collecting three-dimensional ovarian image of a subject by a medical image device,and performing image denoising enhancement treatment; according to the enhanced image, determining the position of the ovarian tumor, and testing the concentration of at least one micromocular biomarker in the ovarian tumor in the subject by using a medical measurement device, and comparing the acquired concentration of the micromocular biomarker with a reference sample; if the concentration of the micromocular biomarker exceeds or is lower than the corresponding threshold value, acquiring CA 125 data, HE4 data and PA data of a to-be-detected serum sample of the subject by using an identification program, and according to the CA 125 data, HE4 data and PA data, calculating the area value of a working characteristic curve, and according to the biomarker level and the area value of the working characteristic curve, evaluating the condition of the ovarian tumor of the subject by using the evaluation program, and generating an evaluation report so that a doctor can make a diagnosis and select therapy methods.

A group of molecular biomarkers having the genes SLC35D3, POSTN, KLK6 and MUC2 can be used in objective and quantitative methods for the classification, prediction of prognosis and for guiding treatment decisions of a subject with colorectal cancer. More specifically, a method for determining the metastatic potential and/or tumor aggressiveness of a colorectal cancer in a subject can include determining the gene expression levels of genes SLC35D3, POSTN, KLK6 and/or MUC2 in a regional lymph node, a primary intestinal tumor, blood, or feces sample obtained from the subject.

Molecular biomarkers as indicators of responses to steroids, drug targets, predictors of steroid responses and identification of drugs for modulating intraocular pressure. Kits and methods of identifying and distinguishing between steroid responders and non-responders.